Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus

OBJECTIVES: Belimumab, an anti-B lymphocyte stimulator (BLyS) human monoclonal antibody, was approved in the United States, Canada and European Union for the treatment of the patients with systemic lupus erythematosus (SLE). However, belimumab had not been evaluated in Japanese patients. The objecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Masanori, Akita, Mikio, Nakagawa, Tomofumi, Takahashi, Naoki, Endo, Akira, Yoshida, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Maney Publishing 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937663/
https://www.ncbi.nlm.nih.gov/pubmed/27536436
http://dx.doi.org/10.3109/21556660.2013.792823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937663/
https://www.ncbi.nlm.nih.gov/pubmed/27536436
http://dx.doi.org/10.3109/21556660.2013.792823

Ejemplares similares